How do the results of ECASS II influence clinical practice of acute stroke treatment?;Como han influido los resultados del estudio ECASS II en la practica clinica del tratamiento de la enfermedad cerebrovascular aguda?

Revista de Neurologia

Volumn 29, Issue 7, 1999, Pages 638-641

  Hacke, W ^a   Ringleb, P ^a   Stingele, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain hemorrhage; European Cooperative Acute Stroke Study; Ischemic stroke; Recombinant tissue plasminogen activator; Streptokinase; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DUTEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PATIENT SELECTION; STROKE; ACUTE DISEASE; BRAIN ISCHEMIA; INTERNATIONAL COOPERATION; REVIEW;

ACUTE DISEASE; BRAIN ISCHEMIA; HUMANS; INTERNATIONAL COOPERATION; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033203223     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2907.99237     Document Type: Conference Paper

References (16)

1. Woo KS, White HD. Comparative tolerability profiles of thrombolytic agents. Drug Safety 1993; 8: 19-29.
2. Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17: 595-607.
3. Haley EC Jr. Thrombolytic therapy for acute ischemic stroke. Clin Neuropharmacol 1993; 16: 179-94.
4. Von Kummer R, Meyding-Lamade U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. Am J Neuroradiol 1994; 15: 9-15.
5. Hacke W, Zeumer H, Ferbert A, et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22.
6. Del Zoppo GJ, Pessin MS, Mori E, et al. Thrombolytic intervention in acute thrombotic and embolic stroke. Sem Neurol 1991; 11: 368-84.
7. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
8. Hacke W. Thrombolytic therapy in acute ischemic stroke: an update. Fibrinolysis 1994; 8 (Suppl 1): 216-20.
9. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
10. Yamaguchi T, Hayakawa T, et al. Intravenous rt-PA in acute embolic stroke. In Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Berlin: Springer-Verlag; 1991. p. 168-74.
11. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333; 1581-7.
12. The multicenter Acute Stroke Trial Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-50.
13. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin and combination of both in acute ischemic stroke. Lancet 1995; 346: 1509-14.
14. Donnan GA, Davis SM, Chambers, et al. Trials of streptokinase in acute ischemic stroke. Lancet 1995; 345: 578-9.
15. Hacke W, Kaste M, Fieschi C, et al. Randomized double blind trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.
16. Furlan AJ. The results of PROACT II. AHA Stroke Conference. Nashville, 1999.